Dronabinol and lofexidine for cannabis use disorder: A randomized, double-blind, placebo-controlled trial

Drug and Alcohol Dependence

Volumn 159, Issue , 2016, Pages 53-60

  Levin, Frances R ^a,b   Mariani, John J ^a,b   Pavlicova, Martina ^c   Brooks, Daniel ^a   Glass, Andrew ^a   Mahony, Amy ^a   Nunes, Edward V ^a,b   Bisaga, Adam ^a,b   Dakwar, Elias ^a,b   Carpenter, Kenneth M ^a,b   Sullivan, Maria A ^a,b   Choi, Jean C ^a  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b College of Physicians and Surgeons of Columbia University ^*  (United States)

^c Columbia University ^*  (United States)

Author keywords

Cannabis use disorder; Cannabis withdrawal; Dronabinol; Lofexidine; Marijuana dependence; Marinol

Indexed keywords

DRONABINOL; LOFEXIDINE; PLACEBO; CANNABINOID RECEPTOR AGONIST; CLONIDINE; NARCOTIC ANTAGONIST;

ADULT; ANXIETY DISORDER; ARTICLE; BEHAVIOR DISORDER ASSESSMENT; CANNABIS ADDICTION; COGNITIVE THERAPY; CONFUSION; CONTROLLED STUDY; DECREASED APPETITE; DEPRESSION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPOTENSION; INSOMNIA; INTOXICATION; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; METEORISM; MOTIVATIONAL ENHANCEMENT AND RELAPSE PREVENTION THERAPY; NAUSEA; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT MONITORING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SMOKING CESSATION; SORE THROAT; SWEAT GLAND DISEASE; TREATMENT DURATION; VOMITING; XEROSTOMIA; ADOLESCENT; ANALOGS AND DERIVATIVES; CRAVING; DRUG EFFECTS; MARIJUANA ABUSE; MEDICATION COMPLIANCE; MIDDLE AGED; SECONDARY PREVENTION; STATISTICS AND NUMERICAL DATA; SUBSTANCE WITHDRAWAL SYNDROME;

ADOLESCENT; ADULT; CANNABINOID RECEPTOR AGONISTS; CLONIDINE; CRAVING; DOUBLE-BLIND METHOD; DRONABINOL; FEMALE; HUMANS; MALE; MARIJUANA ABUSE; MEDICATION ADHERENCE; MIDDLE AGED; NARCOTIC ANTAGONISTS; SECONDARY PREVENTION; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 84955094986     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2015.11.025     Document Type: Article

References (36)

1. American Psychiatric Association American Psychiatric Association (APA). Diagnostic and Statistical Manual of Mental Disorders 1994, American Psychiatric Association, Washington, DC. fourth ed.
2. Allsop D.J., Copeland J., Lintzeris N., Dunlop A.J., Montebello M., Sadler C., Rivas G.R., Holland R.M., Muhleisen P., Norberg M.M., Booth J., McGregor I.S. Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial. JAMA Psychiatry 2014, 71:281-291.
3. Bedi G., Cooper Z.D., Haney M. Subjective, cognitive and cardiovascular dose-effect profile of nabilone and dronabinol in marijuana smokers. Addict. Biol. 2013, 18:872-881.
4. Ben Amar M. Cannabinoids in medicine: a review of their therapeutic potential. J. Ethnopharmacol. 2006, 105:1-25.
5. Budney A.J., Fearer S., Walker D.D., Stanger C., Thostenson J., Grabinski M., Bickel W.K. An initial trial of a computerized behavioral intervention for cannabis use disorder. Drug Alcohol Depend. 2011, 115:74-79.
6. Budney A.J., Moore B.A., Rocha H.L., Higgins S.T. Clinical trial of abstinence-based vouchers and cognitive-behavioral therapy for cannabis dependence. J. Consult. Clin. Psychol. 2006, 74:307-316.
7. Budney A.J., Novy P.L., Hughes J.R. Marijuana withdrawal among adults seeking treatment for marijuana dependence. Addiction 1999, 94:1311-1322.
8. Carpenter K.M., McDowell D., Brooks D.J., Cheng W.Y., Levin F.R. A preliminary trial: double-blind comparison of nefazodone, bupropion-SR, and placebo in the treatment of cannabis dependence. Am. J. Addict. 2009, 18:53-64.
9. Carroll K.M., Rounsaville B.J., Gordon L.T., Nich C., Jatlow P., Bisighini R.M., Gawin F.H. Psychotherapy and pharmacotherapy for ambulatory cocaine abusers. Arch. Gen. Psychiatry 1994, 51:177-187.
10. Cooper Z.D., Haney M. Opioid antagonism enchances marijuana's effects in heavy marijuana smokers. Psychopharmacology (Berl.) 2010, 141-148.
11. Decker S.E., Frankforter T., Babuscio T., Nich C., Ball S.A., Carroll K.M. Assessment concordance and predictive validity of self-report and biological assay of cocaine use in treatment trials. Am. J. Addict. 2014, 23:466-474.
12. Del Boca F.K., Kranzler H.R., Brown J., Korner P.F. Assessment of medication compliance in alcoholics through UV light detection of a riboflavin tracer. Alcohol. Clin. Exp. Res. 1996, 20:1412-1417.
13. Dennis M., Godley S.H., Diamond G., Tims F.M., Babor T., Donaldson J., Liddle H., Titus J.C., Kaminer Y., Webb C., Hamilton N., Funk R. The Cannabis Youth Treatment (CYT) Study: main findings from two randomized trials. J. Subst. Abuse. Treat. 2004, 27:197-213.
14. First M.B., Spitzer R.L., Gibbon M., William J.B.W. Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition (SCID-I/P, Version 2.0) 1995, Biometrics Research Department, New York State Psychiatric Institute.
15. Fraser A.D., Meatherall R. Lack of interference by nabilone in the EMIT D.A.U. cannabinoid assay, Abbott TDx cannabinoid assay, and a sensitive TLC assay for delta 9-THC-carboxylic acid. J. Anal. Toxicol. 1989, 13:240.
16. Gray K.M., Carpenter M.J., Baker N.L., DeSantis S.M., Kryway E., Hartwell K.J., McRae-Clark A.L., Brady K.T. A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents. Am. J. Psychiatry 2012, 169:805-812.
17. Haney M., Cooper Z.D., Bedi G., Vosburg S.K., Comer S.D., Foltin R.W. Nabilone decreases marijuana withdrawal and a laboratory measure of marijuana relapse. Neuropsychopharmacology 2013, 38:1557-1565.
18. Haney M., Hart C.L., Vosburg S.K., Comer S.D., Reed S.C., Foltin R.W. Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse. Psychopharmacology (Berl.) 2008, 197:157-168.
19. Haney M., Hart C.L., Vosburg S.K., Nasser J., Bennett A., Zubaran C., Foltin R.W. Marijuana withdrawal in humans: effects of oral THC or divalproex. Neuropsychopharmacology 2004, 29:158-170.
20. Hart C.L., Haney M., Ward A.S., Fischman M.W., Foltin R.W. Effects of oral THC maintenance on smoked marijuana self-administration. Drug Alcohol Depend. 2002, 67:301-309.
21. Heishman S.J., Singleton E.G., Liguori A. Marijuana Craving Questionnaire: development and initial validation of a self-report instrument. Addiction 2001, 96:1023-1034.
22. Johnson B.A., Ait-Daoud N., Roache J.D. The COMBINE SAFTEE: a structured instrument for collecting adverse events adapted for clinical studies in the alcoholism field. J. Stud. Alcohol Suppl. 2005, 157-167. discussion 140.
23. Johnson B.A., Rosenthal N., Capece J.A., Wiegand F., Mao L., Beyers K., McKay A., Ait-Daoud N., Anton R.F., Ciraulo D.A., Kranzler H.R., Mann K., O'Malley S.S., Swift R.M. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA 2007, 298:1641-1651.
24. Lemberger L., Rubin A., Wolen R., DeSante K., Rowe H., Forney R., Pence P. Pharmacokinetics, metabolism and drug-abuse potential of nabilone. Cancer Treat. Rev. 1982, 9(Suppl. B):17-23.
25. Levin F.R., Mariani J., Brooks D.J., M.P., Cheng C., Nunes E. Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend. 2011, 116:142-150.
26. Levin F.R., Mariani J., Brooks D.J., Pavlicova M., Nunes E.V., Agosti V., Bisaga A., Sullivan M.A., Carpenter K.M. A randomized double-blind, placebo-controlled trial of venlafaxine-extended release for co-occurring cannabis dependence and depressive disorders. Addiction 2013, 108:1084-1094.
27. Levine J., Schooler N.R. SAFTEE: a technique for the systematic assessment of side effects in clinical trials. Psychopharmacol. Bull. 1986, 22:343-381.
28. Mariani J.J., Brooks D., Haney M., Levin F.R. Quantification and comparison of marijuana smoking practices: Blunts, joints, and pipes. Drug Alcohol Depend. 2011, 113(2-3):CD008940.
29. Marshall K., Gowing L., Ali R., Le Foll B. Pharmacotherapies for cannabis dependence. Cochrane Database Syst. Rev. 2014, 12:CD008940.
30. McRae A.L., Budney A.J., Brady K.T. Treatment of marijuana dependence: a review of the literature. J. Subst. Abuse Treat. 2003, 24:369-376.
31. Nunes E.V., Quitkin F.M., Donovan S.J., Deliyannides D., Ocepek-Welikson K., Koenig T., Brady R., McGrath P.J., Woody G. Imipramine treatment of opiate-dependent patients with depressive disorders. A placebo-controlled trial. Arch. Gen. Psychiatry 1998, 55:153-160.
32. Substance Abuse and Mental Health Services Administration Publication No. (SMA) 14-4863 2014, Substance Abuse and Mental Health Services Administration, Rockville, MD, Available online at 〈http://www.samhsa.gov/data/sites/default/files/NSDUHresultsPDFWHTML2013/Web/NSDUHresults2013.pdf〉 (accessed on July 22, 2015).
33. Sinha R., Kimmerling A., Doebrick C., Kosten T.R. Effects of lofexidine on stress-induced and cue-induced opioid craving and opioid abstinence rates: preliminary findings. Psychopharmacology (Berl.) 2007, 190:569-574.
34. Sobell L.C., Sobell M.B. Timeline follow-back: a technique for assessing self-reported alcohol consumption. Measuring Alcohol Consumption 1992, Humana Press, Totowa, NJ.
35. Steinberg K., Roffman R., Carroll K., McRee B., Babor T., Miller M., Kadden R., Duresky D., Stephens R. Brief Counseling for Marijuana Dependence 2005, Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration, Rockville, MD.
36. Wilens T.E., Adler L.A., Weiss M.D., Michelson D., Ramsey J.L., Moore R.J., Renard D., Brady K.T., Trzepacz P.T., Schuh L.M., Ahrbecker L.M., Levine L.R. Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders. Drug Alcohol Depend. 2008, 96:145-154.